Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Comment by forhandlarenon Feb 19, 2024 2:58am
113 Views
Post# 35887260

RE:Revenue forecast

RE:Revenue forecastThe initial lauch is planned for USA and Canada Q1 2025. The products are expected to be launched in Europe, Guld states and Australia New Zealand starting Q4 2025. China, Japan and South Korea in 2026. A two year rollout.

A forecast is a forecast. I took the liberty to extrapolate the numbers by Iscfa into year two and ended up with stellar numbers - not counting Maintencance sales. In addition there's potential for third party launch according to the interview with Geraldine lately. Total margin is 90 percent.

Units sold year two (aggregate): 1 222 654
Revenue: 305 663 448

Should we assume that sales revenue is USD that should be converted into CAD with a factor of 1.3 to be translated into revenue per share? That's my assumption.

If - and that's a big IF - the sales forecast is anywhere close to reality, we're looking at a multi-dollar share in two years even if a conservative P/E 8 would be applied.
<< Previous
Bullboard Posts
Next >>